Form 4: BeiGene Director Alessandro Riva Reports Acquisition of Shares and Options

Director Alessandro Riva acquired 16,341 ordinary shares and options for 34,151 ordinary shares of BeiGene, Ltd.

Summary

• On June 5, 2024, Alessandro Riva, a director of BeiGene, Ltd., reported acquiring 16,341 ordinary shares.
• These shares were acquired at a price of $0.
• Following the transaction, Riva beneficially owns 45,955 ordinary shares.
• Riva also acquired options for 34,151 ordinary shares with an exercise price of $12.23.
• The options become exercisable on the earlier of the first anniversary of the grant date or the next annual general meeting and expire on June 4, 2034.
• The restricted share units and options were granted under the Company's Independent Director Compensation Policy, as amended.
• Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options by a director is generally viewed as a positive sign, but it's not a major event.

Positives

• A director increasing their stake in the company can be seen as a positive signal.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting and exercisability of the shares and options are tied to Riva's continued service as a director and potential change in control events.

Industry Context

This filing is a routine disclosure related to insider transactions. It's common for directors and officers of publicly traded companies to receive stock options and restricted stock units as part of their compensation packages. These grants are designed to align the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry, used to incentivize and retain talent.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedules and terms outlined in this filing appear to be standard within the industry.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's confidence in the company.
• The vesting conditions tied to continued service as a director incentivize the director to remain with the company.

Key Dates